Human mesenchymal stem cells (MSCs) can be isolated from various tissues. However, the cytokine profile in different MSC types remains unclear. In this study, MSCs were extracted from adipose, umbilical cord, and placental tissues. The surface marker expression, multilineage differentiation potential, and cytokine secretion of these cells were compared. The isolated MSCs exhibited similar morphology and surface marker expression. However, they differed with regard to their differentiation potential. Adipose-MSCs (A-MSCs) exhibited a higher potential for adipogenesis and osteogenic differentiation compared with umbilical cord-MSCs (UC-MSCs) and placental-MSCs (P-MSCs). The expression levels of 80 cytokines were detected, and the data demonstrated that the three MSC types abundantly secreted insulin-like growth factor-binding protein (IGFBP)-4, IGFBP-3, tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2, IGFBP-6, monocyte chemoattractant protein-1, and granulocyte colony-stimulating factor. However, the expression levels of vascular endothelial growth factor, tumor necrosis factor alpha, interleukin (IL)-6 receptor, and IL-13 in A-MSCs were higher compared with those of UC-MSCs and P-MSCs. Moreover, the expression levels of intercellular adhesion molecule-1 and growth differentiation factor 15 were lower in A-MSCs. Kyoto Encyclopedia of Genes and Genomes analysis indicated that the “adipocytokine” and the “PI3K/Akt pathways” were enriched in A-MSCs. Taken together, the results demonstrated that MSCs from different sources exhibited differences in the secretion of specific factors. A-MSCs were associated with the expression of several proangiogenic factors and may be an improved source for angiogenesis and tissue regeneration.
Get full access to this article
View all access options for this article.
References
1.
AnbarasanC., BavanilathaM., LatchumanadhasK., and Ajit MullasariS. (2015). ICAM-1 molecular mechanism and genome wide SNP's association studies. Indian Heart J. 67, 282–287.
2.
AnderliniP., and ChamplinR.E. (2008). Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: Recent findings and current challenges. Blood. 111, 1767–1772.
3.
ApteR.S., ChenD.S., and FerraraN. (2019). VEGF in signaling and disease: Beyond discovery and development. Cell. 176, 1248–1264.
4.
BurjaB., BarličA., ErmanA., Mrak-PoljšakK., TomšičM., Sodin-SemrlS., and LakotaK. (2020). Human mesenchymal stromal cells from different tissues exhibit unique responses to different inflammatory stimuli. Curr. Res. Transl. Med. 68, 217–224.
5.
ChenJ., CrawfordR., ChenC., and XiaoY. (2013). The key regulatory roles of the PI3K/Akt signaling pathway in the functionalities of mesenchymal stem cells and applications in tissue regeneration. Tissue Eng. Part. B. Rev. 19, 516–528.
6.
ClarkeM.R., ImhoffF.M., and BairdS.K. (2015). Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase-1 and -2. Mol. Carcinog. 54, 1214–1219.
7.
DingC., LiH., WangY., WangF., WuH., ChenR., LvJ., WangW., and HuangB. (2017). Different therapeutic effects of cells derived from human amniotic membrane on premature ovarian aging depend on distinct cellular biological characteristics. Stem Cell Res. Ther. 8,173.
8.
Di TarantoG., CicioneC., ViscontiG., IsgròM.A., BarbaM., Di StasioE., StiglianoE., BernardiniC., MichettiF., SalgarelloM., and LattanziW. (2015). Qualitative and quantitative differences of adipose-derived stromal cells from superficial and deep subcutaneous lipoaspirates: A matter of fat. Cytotherapy. 17, 1076–1089.
9.
DjouadF., CharbonnierL.M., BouffiC., Louis-PlenceP., BonyC., ApparaillyF., CantosC., JorgensenC., and NoëlD. (2007). Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 25, 2025–2032.
10.
DohertyT.M., KasteleinR., MenonS., AndradeS., and CoffmanR.L. (1993). Modulation of murine macrophage function by IL-13. J. Immunol. 151, 7151–7160.
11.
DooleyD., LemmensE., VangansewinkelT., Le BlonD., HoornaertC., PonsaertsP., and HendrixS. (2016). Cell-based delivery of interleukin-13 directs alternative activation of macrophages resulting in improved functional outcome after spinal cord injury. Stem Cell Rep. 7, 1099–1115.
12.
DoyleA.G., HerbeinG., MontanerL.J., MintyA.J., CaputD., FerraraP., and GordonS. (1994). Interleukin-13 alters the activation state of murine macrophages in vitro: Comparison with interleukin-4 and interferon-gamma. Eur. J. Immunol. 24, 1441–1445.
13.
DriscollJ., and PatelT. (2019). The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease. J. Gastroenterol. 54, 763–773.
14.
El-SayedM., El-FekyM.A., El-AmirM.I., HasanA.S., Tag-AdeenM., UrataY., GotoS., LuoL., YanC., and LiT.S. (2019). Immunomodulatory effect of mesenchymal stem cells: Cell origin and cell quality variations. Mol. Biol. Rep. 46, 1157–1165.
15.
GabrM.M., ZakariaM.M., RefaieA.F., Abdel-RahmanE.A., RedaA.M., AliS.S., KhaterS.M., AshamallahS.A., IsmailA.M., IsmailH., El-BadriN., and GhoneimM.A. (2017). From human mesenchymal stem cells to insulin-producing cells: Comparison between bone marrow- and adipose tissue-derived cells. BioMed Res. Int. 2017,3854232.
16.
GangadaranP., RajendranR.L., LeeH.W., KalimuthuS., HongC.M., JeongS.Y., LeeS.W., LeeJ., and AhnB.C. (2017). Extracellular vesicles from mesenchymal stem cells activates VEGF receptors and accelerates recovery of hindlimb ischemia. J. Control. Release. 264, 112–126.
17.
GeQ., ZhangH., HouJ., WanL., ChengW., WangX., DongD., ChenC., XiaJ., GuoJ., ChenX., and WuX. (2018). VEGF secreted by mesenchymal stem cells mediates the differentiation of endothelial progenitor cells into endothelial cells via paracrine mechanisms. Mol. Med. Rep. 17, 1667–1675.
18.
GolchinA., and FarahanyT.Z. (2019). Biological products: Cellular therapy and FDA approved products. Stem Cell Rev. Rep. 15, 166–175.
19.
GolchinA., FarahanyT.Z., KhojastehA., SoleimanifarF., and ArdeshirylajimiA. (2019). The clinical trials of mesenchymal stem cell therapy in skin diseases: An update and concise review. Curr. Stem Cell Res. Ther. 14, 22–33.
20.
GrégoireC., RitaccoC., HannonM., SeidelL., DelensL., BelleL., DuboisS., VériterS., LechanteurC., BriquetA., ServaisS., EhxG., BeguinY., and BaronF. (2019). Comparison of mesenchymal stromal cells from different origins for the treatment of graft-vs.-host-disease in a humanized mouse model. Front. Immunol. 10, 619.
21.
HassR., KasperC., BöhmS., and JacobsR. (2011). Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell. Commun. Signal. 9,12.
22.
HoferH.R., and TuanR.S. (2016). Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies. Stem Cell Res. Ther. 7,131.
23.
HoornaertC.J., LuyckxE., ReekmansK., DhainautM., GuglielmettiC., Le BlonD., DooleyD., FransenE., DaansJ., VerbeeckL., QuartaA., De VochtN., LemmensE., GoossensH., Van der LindenA., RoobrouckV.D., VerfaillieC., HendrixS., MoserM., BernemanZ.N., and PonsaertsP. (2016). In vivo interleukin-13-primed macrophages contribute to reduced alloantigen-specific T cell activation and prolong immunological survival of allogeneic mesenchymal stem cell implants. Stem Cells. 34, 1971–1984.
24.
JinH.J., BaeY.K., KimM., KwonS.J., JeonH.B., ChoiS.J., KimS.W., YangY.S., OhW., and ChangJ.W. (2013). Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int. J. Mol. Sci. 14, 17986–18001.
25.
KabatM., BobkovI., KumarS., and GrumetM. (2020) Trends in mesenchymal stem cell clinical trials 2004–2018: Is efficacy optimal in a narrow dose range? Stem Cells Transl. Med. 9:17–27.
26.
KarnieliO., FriednerO.M., AllicksonJ.G., ZhangN., JungS., FiorentiniD., AbrahamE., EakerS.S., YongT.K., ChanA., GriffithsS., WehnA.K., OhS., and KarnieliO. (2017). A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy. 19, 155–169.
27.
KimD.H., LeeD., LimH., ChoiS.J., OhW., YangY.S., ChangJ.H., and JeonH.B. (2018). Effect of growth differentiation factor-15 secreted by human umbilical cord blood-derived mesenchymal stem cells on amyloid beta levels in in vitro and in vivo models of Alzheimer's disease. Biochem. Biophys. Res. Commun. 504, 933–940.
28.
KimM.J., ShinK.S., JeonJ.H., LeeD.R., ShimS.H., KimJ.K., ChaD.H., YoonT.K., and KimG.J. (2011). Human chorionic-plate-derived mesenchymal stem cells and Wharton's jelly-derived mesenchymal stem cells: A comparative analysis of their potential as placenta-derived stem cells. Cell Tissue Res. 346, 53–64.
29.
KraskiewiczH., PaprockaM., Bielawska-PohlA., KrawczenkoA., PanekK., KaczyńskaJ., SzyposzyńskaA., PsurskiM., KuropkaP., and KlimczakA. (2020). Can supernatant from immortalized adipose tissue MSC replace cell therapy? An in vitro study in chronic wounds model. Stem Cell Res. Ther. 11,29.
30.
KurdiM., and BoozG.W. (2007). G-CSF-based stem cell therapy for the heart-unresolved issues part A: Paracrine actions, mobilization, and delivery. Congest. Heart Fail. 13, 221–227.
31.
LiC.Y., Wu. X.Y., Tong. J.B., YangX.X., ZhaoJ.L., ZhengQ.F., ZhaoG.B., and MaZ.J. (2015). Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy. Stem Cell Res. Ther. 6,55.
32.
LiF., LiuH., ZhangK., XiaoD.J., WangC., and WangY.S. (2021). Adipose-derived stromal cells improve functional recovery after spinal cord injury through TGF-β1/Smad3/PLOD2 pathway activation. Aging. 13, 4370–4387.
33.
LiF., ZhangK., LiuH., YangT., XiaoD.J., and WangY.S. (2020). The neuroprotective effect of mesenchymal stem cells is mediated through inhibition of apoptosis in hypoxic ischemic injury. WJP. 16, 193–200.
34.
LiX., WangQ., DingL., WangY.X., ZhaoZ.D., MaoN., WuC.T., WangH., TangB., LiX., LiuY., ChenX., LiX., ChuY., ZhuH., LiuW., XuF., ZhouF., and ZhangY. (2018). The therapeutic effect of ICAM-1-overexpressing mesenchymal stem cells on acute graft-versus-host disease. Cell. Physiol. Biochem. 46, 2624–2635.
35.
LiuM., LeiH., DongP., FuX., YangZ., YangY., MaJ., LiuX., CaoY., and XiaoR. (2017). Adipose-derived mesenchymal stem cells from the elderly exhibit decreased migration and differentiation abilities with senescent properties. Cell Transplant. 26, 1505–1519.
36.
LofqvistC., ChenJ., ConnorK.M., SmithA.C., AdermanC.M., LiuN., PintarJ.E., LudwigT., HellstromA., and SmithL.E. (2007). IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc. Natl. Acad. Sci. U. S. A. 104, 10589–10594.
37.
LugerD., LipinskiM.J., WestmanP.C., GloverD.K., DimastromatteoJ., FriasJ.C., AlbeldaM.T., SikoraS., KharaziA., VertelovG., WaksmanR., and EpsteinS.E. (2017). Intravenously delivered mesenchymal stem cells: Systemic anti-inflammatory effects improve left ventricular dysfunction in acute myocardial infarction and ischemic cardiomyopathy. Circ. Res. 120, 1598–1613.
38.
MatasJ., OrregoM., AmenabarD., InfanteC., Tapia-LimonchiR., CadizM.I., Alcayaga-MirandaF., GonzálezP.L., MuseE., KhouryM., FigueroaF.E., and EspinozaF. (2019). Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: Repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. Stem Cells Transl. Med. 8, 215–224.
39.
MatsumotoK., and EmaM. (2014). Roles of VEGF-A signalling in development, regeneration, and tumours. J. Biochem. 156, 1–10.
40.
MengX., SunB., and XiaoZ. (2019). Comparison in transcriptome and cytokine profiles of mesenchymal stem cells from human umbilical cord and cord blood. Gene. 696, 10–20.
41.
MoghadamM., TokhanbigliS., BaghaeiK., FarivarS., Asadzadeh AghdaeiH., and ZaliM.R. (2020). Gene expression profile of immunoregulatory cytokines secreted from bone marrow and adipose derived human mesenchymal stem cells in early and late passages. Mol. Biol. Rep. 47, 1723–1732.
42.
MunC.H., KangM.I., ShinY.D., KimY., and ParkY.B. (2018). The expression of immunomodulation-related cytokines and genes of adipose- and bone marrow-derived human mesenchymal stromal cells from early to late passages. Tissue Eng. Regen. Med. 15, 771–779.
43.
MurphyK.C., WhiteheadJ., FalaheeP.C., ZhouD., SimonS.I., and LeachJ.K. (2017). Multifactorial experimental design to optimize the anti-inflammatory and proangiogenic potential of mesenchymal stem cell spheroids. Stem Cells. 35, 1493–1504.
44.
NakajimaH., UchidaK., GuerreroA.R., WatanabeS., SugitaD., TakeuraN., YoshidaA., LongG., WrightK.T., JohnsonW.E., and BabaH. (2012). Transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury. J. Neurotrauma. 29, 1614–1625.
45.
NiuH., GouR., XuQ., and DuanD. (2017). Recombinant insulin-like growth factor binding protein-4 inhibits proliferation and promotes differentiation of neural progenitor cells. Neurosci. Lett. 642, 71–76.
46.
OuyangS., LiW., LiuZ., LiY., LiS., and WuJ. (2016). Association between serum soluble tumor necrosis factor-α receptors and early childhood obesity. Endocr. J. 63, 581–587.
47.
ParkC.W., KimK.S., BaeS., SonH.K., MyungP.K., HongH.J., and KimH. (2009). Cytokine secretion profiling of human mesenchymal stem cells by antibody array. Int. J. Stem Cells. 2, 59–68.
48.
PetrouP., GothelfY., ArgovZ., GotkineM., LevyY.S., KassisI., Vaknin-DembinskyA., Ben-HurT., OffenD., AbramskyO., MelamedE., and KarussisD. (2016). Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: Results of phase 1/2 and 2a clinical trials. JAMA Neurol. 73, 337–344.
49.
PhedyP., DjajaY.P., GatamL., KusnadiY., WirawanR.P., TobingI.M.S., SubakirN., MappaliluA., PrawiraM.A., YauwenasR., and GatamA.R. (2019). Motoric recovery after transplantation of bone marrow derived mesenchymal stem cells in chronic spinal cord injury: A case report. Am. J. Case Rep. 20, 1299–1304.
50.
RiesC. (2014). Cytokine functions of TIMP-1. Cell Mol. Life Sci. 71, 659–672.
51.
RyuH.H., KangB.J., ParkS.S., KimY., SungG.J., WooH.M., KimW.H., and KweonO.K. (2012). Comparison of mesenchymal stem cells derived from fat, bone marrow, Wharton's jelly, and umbilical cord blood for treating spinal cord injuries in dogs. J. Vet. Med. Sci. 74, 1617–1630.
52.
SamakovaA., GazovaA., SabovaN., ValaskovaS., JurikovaM., and KyselovicJ. (2019). The PI3k/Akt pathway is associated with angiogenesis, oxidative stress and survival of mesenchymal stem cells in pathophysiologic condition in ischemia. Physiol. Res. 68, S131–S138.
53.
SattiH.S., WaheedA., AhmedP., AhmedK., AkramZ., AzizT., SattiT.M., ShahbazN., KhanM.A., and MalikS.A. (2016). Autologous mesenchymal stromal cell transplantation for spinal cord injury: A Phase I pilot study. Cytotherapy. 18, 518–522.
54.
SawS., AikenA., FangH., McKeeT.D., BregantS., SanchezO., ChenY., WeissA., DicksonB.C., CzarnyB., SinhaA., FosangA., DiveV., WaterhouseP.D., KislingerT., and KhokhaR. (2019). Metalloprotease inhibitor TIMP proteins control FGF-2 bioavailability and regulate skeletal growth. J. Cell Biol. 218, 3134–3152.
55.
SchmelzerE., McKeelD.T., and GerlachJ.C. (2019). Characterization of human mesenchymal stem cells from different tissues and their membrane encasement for prospective transplantation therapies. BioMed Res. Int. 2019,6376271.
56.
SharmaR.R., PollockK., HubelA., and McKennaD. (2014). Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices. Transfusion. 54, 1418–1437.
57.
SilvaD.N., SouzaB., VasconcelosJ.F., AzevedoC.M., ValimC., ParedesB.D., RochaV., CarvalhoG.B., DaltroP.S., MacambiraS.G., NonakaC., Ribeiro-Dos-SantosR., and SoaresM. (2018). Granulocyte-colony stimulating factor-overexpressing mesenchymal stem cells exhibit enhanced immunomodulatory actions through the recruitment of suppressor cells in experimental chagas disease cardiomyopathy. Front. Immunol. 9,1449.
58.
TangB., LiX., LiuY., ChenX., LiX., ChuY., ZhuH., LiuW., XuF., ZhouF., and ZhangY. (2018). The therapeutic effect of ICAM-1-overexpressing mesenchymal stem cells on acute Graft-Versus-Host Disease. Cell Physiol. Biochem. 46, 2624–2635.
59.
TekkatteC., GunasinghG.P., CherianK.M., and SankaranarayananK. (2011). “Humanized” stem cell culture techniques: The animal serum controversy. Stem Cells Int. 2011,504723.
WangL., HuangS., LiS., LiM., ShiJ., BaiW., WangQ., ZhengL., and LiuY. (2019). Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: A prospective phase I/II study. Drug Design Dev. Ther. 13, 4331–4340.
62.
WeiH., LiuX., OuyangC., ZhangJ., ChenS., LuF., and ChenL. (2017). Complications following stem cell therapy in inflammatory bowel disease. Curr. Stem Cell Res. Ther. 12, 471–475.
63.
WeiZ.J., WangQ.Q., CuiZ.G., InaderaH., JiangX., and WuC.A. (2021). Which is the most effective one in knee osteoarthritis treatment from mesenchymal stem cells obtained from different sources?. A systematic review with conventional and network. meta-analyses of randomized controlled trials. Ann. Transl. Med. 9, 452.
64.
WeisslederC., BarryG., FungS.J., WongM.W., DoubleK.L., WebsterM.J., and WeickertC.S. (2019). Reduction in IGF1 mRNA in the human subependymal zone during aging. Aging Dis. 10, 197–204.
65.
WuM., ZhangR., ZouQ., ChenY., ZhouM., LiX., RanR., and ChenQ. (2018). Comparison of the biological characteristics of mesenchymal stem cells derived from the human placenta and umbilical cord. Sci. Rep. 8,5014.
66.
YangY., PangM., DuC., LiuZ.Y., ChenZ.H., WangN.X., ZhangL.M., ChenY.Y., MoJ., DongJ.W., XieP.G., WangQ.Y., LiuB., and RongL.M. (2021). Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: A phase 1/2 pilot study. Cytotherapy. 23, 57–64.
67.
ZhangJ., LvS., LiuX., SongB., and ShiL. (2018). Umbilical cord mesenchymal stem cell treatment for Crohn's disease: A randomized controlled clinical trial. Gut Liver. 12, 73–78.
68.
ZhaoL., ChenS., YangP., CaoH., and LiL. (2019). The role of mesenchymal stem cells in hematopoietic stem cell transplantation: Prevention and treatment of graft-versus-host disease. Stem Cell Res. Ther. 10,182.
69.
ZhouL., SongQ., ShenJ., XuL., XuZ., WuR., GeY., ZhuJ., WuJ., DouQ., and JiaR. (2017). Comparison of human adipose stromal vascular fraction and adipose-derived mesenchymal stem cells for the attenuation of acute renal ischemia/reperfusion injury. Sci. Rep. 7,44058.
70.
ZhuH., and NingS.B. (2019). Intercellular adhesion molecule-1 enhances the therapeutic effects of MSCs in a dextran sulfate sodium-induced colitis models by promoting MSCs homing to murine colons and spleens. Stem Cell Res. Ther. 10,267.
71.
ZhuX.Y., MaS., EirinA., WoollardJ.R., HicksonL.J., SunD., LermanA., and LermanL.O. (2016). Functional plasticity of adipose-derived stromal cells during development of obesity. Stem Cells Transl. Med. 5, 893–900.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
